Analysis of relations with cSrc and the radiation therapy in head and neck cancer patient

• Project/Area Number: 23791939
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Otorhinolaryngology
• Research Institution: Juntendo University
• Principal Investigator: MATSUMOTO Fumihikoa 順天堂大学, 医学部, 准教授 (70445584)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
• Keywords: 頭頸部外科学 / cSrc / 放射線 / EGFR / IGF1R / 頭頸部扁平上皮癌 / 放射線治療

Research Abstract

The specimen was obtained by biopsy or surgery from patient was investigated by immunohistochemistry . The patients have high expression level of cSrc is more resistant to radiotherapy than low expression. Furthermore, the combination effect of anti IGF-1R and EGFR antibody and radiotherapy to head and neck cancer cell was examined in xenograft mouse model. The combination of anti-EGFR and IGF-1R and radiation showed high antitumor effect.

Research Products

• [Journal Article] The Impact of Timing of EGFR and IGF-1R Inhibition for Sensitizing (2012)
  • Author(s): Matsumoto F, Valdecanas DN, Mason KA, Milas L, Ang KK, Raju U
  • Journal Title: Head and Neck Cancer to Radiation. Anticancer Res Volume: 32(8) Pages: 3029-35
• [Journal Article] The Impact of Timing of EGFR and IGF-1R Inhibition for Sensitizing (2012)
  • Author(s): Matsumoto F
  • Journal Title: Head and Neck Cancer to Radiation.Anticancer Res. Volume: 32(8) Pages: 3029-35
  • Peer Reviewed
• [Journal Article] A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe (2011)
  • Author(s): Riesterer O, Matsumoto F, Wang L, Pickett J, Molkentine D, Giri U, Milas L, Raju U
  • Journal Title: Invest New Drugs Volume: 29 Pages: 514-22
• [Journal Article] Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. (2011)
  • Author(s): Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN
  • Journal Title: Clin Cancer Res Volume: 17 Pages: 1815-27